
Fulltext:
50926.pdf
Embargo:
until further notice
Size:
199.0Kb
Format:
PDF
Description:
Publisher’s version
Publication year
2006Source
Clinica Chimica Acta, 368, 1-2, (2006), pp. 20-32ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Clinical Chemistry
Urology
Journal title
Clinica Chimica Acta
Volume
vol. 368
Issue
iss. 1-2
Page start
p. 20
Page end
p. 32
Subject
IGMD 7: Iron metabolism; N4i 1: Pathogenesis and modulation of inflammation; NCEBP 1: Molecular epidemiology; ONCOL 1: Hereditary cancer and cancer-related syndromes; ONCOL 3: Translational research; ONCOL 5: Aetiology, screening and detection; UMCN 1.2: Molecular diagnosis, prognosis and monitoring; UMCN 5.1: Genetic defects of metabolismAbstract
Expression of the anti-apoptotic protein survivin is hardly detectable or even absent in many differentiated adult tissues, but is upregulated in almost any type of cancer. Furthermore, high survivin mRNA or protein expression generally correlates with an adverse disease course. Both these important features of survivin expression have been investigated for diagnostic and prognostic purposes in many human cancers, including bladder cancer. In this review, the role of survivin in the detection of bladder tumors and the prediction of tumor recurrence in patients with superficial bladder cancer will be discussed and compared to that of other markers/tests. The most promising marker(s) will be outlined. Also, important requirements for a successful implementation of such markers in a hospital setting are discussed. Finally, future directions for the discovery of new diagnostic or prognostic candidate markers will be mentioned.
This item appears in the following Collection(s)
- Academic publications [227088]
- Electronic publications [108509]
- Faculty of Medical Sciences [86606]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.